Skip to content
FINTERY
Industry briefing

Life Sciences in Europe

Pharmaceuticals plus healthcare and biotech - 2025-2026 outlook

Executive summary•Public preview

Key statistic

Eurostat put EU healthcare expenditure at 10.0% of GDP in 2023, while pharmaceutical sold production reached EUR 263 billion in 2024 - so demand is there, but the constraint is execution under regulation.

Why it matters

Life sciences is one of the few European sectors where demand, innovation and regulation all intensified at once. That creates opportunity, but only for teams that can handle data interoperability, patient and HCP access, regulatory evidence and increasingly AI-enabled workflows under strong governance. EUR 263bn 2024 sold production in pharmaceutical products EUR 55bn R&D; invested by Europe's research-based pharma industry in 2024 10.0% EU healthcare expenditure as a share of GDP in 2023

Executive summary

The sector is expanding, but execution is constrained by regulation, fragmented data and health-system capacity. The winners in 2025-2026 will be those that simplify evidence generation, modernise regulatory and clinical operations, and improve access, engagement and service without losing compliance discipline. In healthcare delivery, the immediate question is workforce and capacity. In biotech and pharma, the question is how to use data and AI responsibly to accelerate development, market access and operational resilience. Europe is digitising, but health and life-science use cases demand stronger governance than most sectors. AI and data programs need documented controls, interoperability and explicit legal review much earlier than typical enterprise automation projects.

Premium wall

The full pack adds the action agenda, regulation watch, provider landscape, and deeper operating guidance behind this teaser.

Unlock full packBook Florian directly

Who should read this

  • Life-sciences, healthcare, and biotech teams working under evidence, access, and regulatory constraints.
  • Commercial and medical leaders responsible for governed engagement and market access quality.
  • Data and operations teams modernising regulatory, clinical, or care workflows.

Three next-step questions

  1. Which evidence, documentation, or approval workflow creates the most friction today?
  2. Where could one governed AI or automation use case remove administrative load without increasing risk?
  3. How reusable and interoperable are the data assets behind clinical, regulatory, and commercial decisions?

Premium industry pack

Life Sciences in Europe

The public summary is designed to be genuinely useful. The paid pack goes further into operating implications, action agenda, watch-outs, and provider landscape.

What the full pack includes

Pharma and health-system demand signals, AI and data implications, regulatory watchlist, action agenda and illustrative provider categories. To stay within a nine-pack structure, this briefing combines pharmaceuticals with healthcare and biotech, focusing on shared implications for commercialisation, regulation, data and product development.

Single pack

EUR 149

Analyst-style PDF
Get the full 9-pack bundle

If the issue is cross-functional, multi-industry, or still unclear, the better route is usually a short founder call instead of buying one pack in isolation.

Book a call with Florian

Beyond one pack

If the issue spans multiple functions, use the briefing as context and then scope it properly

These packs are designed to sharpen judgment fast. If your situation cuts across multiple teams, countries, or systems, a short call with Florian is usually the better next step.

Book a Strategy CallSend a structured inquiry